LAUSR

The sphingosine-1-phosphate (S1P) signaling pathway is an attractive drug target due to its involvement in immune cell chemotaxis and vascular integrity. The formation of S1P is catalyzed by sphingosine kinase 1 or 2 (SphK1 or SphK2) from sphingosine (Sph) and ATP. Inhibition of SphK1 and 2 to attenuate levels of S1P has been reported to be efficacious in animal models of diseases such as cancer, sickle cell disease and renal fibrosis. While inhibitors of both SphKs have been reported, improvements in potency and selectivity are still needed. Towards that end, we performed a structure-activity relationship profiling of 8 (SLM6031434) and discovered a heretofore unrecognized side cavity that increased inhibitor potency toward SphK2. Interrogating this region revealed that relatively small hydrophobic moieties are preferred with 10 being the most potent SphK2 selective inhibitor (Ki = 89 nM, 73-fold SphK2 selective) with validated in vivo activity.